BF-200 ALA and red light LED lamp

COMBINATION_PRODUCT3 trials

Sponsors

Biofrontera Bioscience GmbH, Biofrontera Inc.

Conditions

Actinic KeratosesActinic KeratosisKeratosisKeratosis, Actinic

Phase 1

Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)

CompletedNCT04319159

Biofrontera Bioscience GmbHActinic Keratoses

Start: 2020-03-05End: 2020-10-07Updated: 2021-11-11

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

CompletedNCT05060237

Biofrontera Bioscience GmbHActinic Keratosis, Keratosis, Keratosis, Actinic

Start: 2021-12-01End: 2023-04-20Updated: 2024-10-17

Phase 3

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

CompletedNCT05662202

Biofrontera Inc.Actinic Keratoses

Start: 2022-12-12End: 2026-07-01Updated: 2026-08-21